National Edu News: CBSE Awards for Teaching and School Leadership 2020-21, Apply till June 28th  |  Technology Inceptions: Microsoft Surface Laptop 4 for Commercial and Education Purposes  |  Technology Inceptions: 'Sunwatch' to Detect Harmful UV Rays  |  Science Innovations: High Power Laster to Deflect Lightning  |  Parent Interventions: A Guide to Parenting in Times of Pandemic  |  Guest Column: The Death of the Creative Writer!  |  Teacher Insights: Why the Boom in Private Tuition Business?  |  Technology Inceptions: More Heat Resilient Silver Circuitry  |  Science Innovations: Silica Nanoparticles for Precise Drug Targetting  |  National Edu News: IIT Hyderabad Improves in QS World University Rankings to 591-600  |  Technology Inceptions: C02 Emissions to Be Made into Animal Feed  |  Leadership Instincts: Blockchain Helping UN Interventions to End Poverty and Hunger  |  National Edu News: Three Indian Institutions in Top 200 of QS World University Rankings  |  Management lessons: Vaccines, Social Distancing, Facemasks Essential Tools to Fight Covid-19  |  Education Information: “The Language Network” to revolutionise language learning  |  
May 06, 2021 Thursday 06:03:44 PM IST

Scientists develop new class of cancer drug with potential to treat leukaemia

Scientists have made a promising step towards developing a new drug for treating acute myeloid leukaemia, a rare blood disorder. In a study published today in Nature, Cambridge researchers report a new approach to cancer treatment that targets enzymes which play a key role in translating DNA into proteins and which could lead to a new class of cancer drugs. Our genetic code is written in DNA, but in order to generate proteins – molecules that are vital to the function of living organisms – DNA first needs to be converted into RNA. The production of proteins is controlled by enzymes, which make chemical changes to RNA. Occasionally these enzymes become mis-regulated, being produced in over-abundance.

In a study published in 2017, a team led by Professor Tony Kouzarides from the Milner Therapeutics Institute and the Gurdon Institute at the University of Cambridge showed how one such enzyme, METTL3, plays a key role in the development and maintenance of acute myeloid leukaemia. The enzyme becomes over-expressed – that is, over-produced – in certain cell types, leading to the disease. Acute myeloid leukaemia (AML) is a cancer of the blood in which bone marrow produces abnormal white blood cells known as myeloid cells, which normally protect the body against infection and against the spread of tissue damage. AML proceeds rapidly and aggressively, usually requiring immediate treatment, and affects both children and adults. Around 3,100 people are diagnosed with the condition every year in the UK, the majority of whom are over 65 years of age.

Now, Professor Kouzarides and colleagues at STORM Therapeutics, a Cambridge spinout associated with his team, and the Wellcome Sanger Institute, have identified a drug-like molecule, STM2457, that can inhibit the action of METTL3. In tissue cultured from individuals with AML and in mouse models of the disease, the team showed that the drug was able to block the cancerous effect caused by over-expression of the enzyme. To investigate the anti-leukaemic potential of STM2457, the researchers tested the drug on cell lines derived from patients with AML and found that the drug significantly reduced the growth and proliferation of these cells. It also induced apoptosis – ‘cell death’ – killing off the cancerous cells. The researchers transplanted cells from patients with AML into immunocompromised mice to model the disease. When they treated the mice with STM2457, they found that it impaired the proliferation and expansion of the transplanted cells and significantly prolonged the lifespan of the mice. It reduced the number of leukaemic cells in the mouse bone marrow and spleen, while showing no toxic side effects, including no effect on body weight.